
Results of the 1996 T-Lymphocyte Immunophenotyping Questionnaire Survey Mailed to Laboratories Participating in the Model Performance Evaluation Program



T-Lymphocyte Immunophenotyping By Multi-Platform and Single-Platform Methods



U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Centers for Disease Control and Prevention



Report of results for a 1996 T-lymphocyte Immunophenotyping (TLI) laboratory questionnaire survey mailed to laboratories participating in the Model Performance Evaluation Program, Centers for Disease Control and Prevention (CDC)

Production of this report was coordinated in CDC by:
Public Health Practice Program Office Edward L. Baker, M.D., M.P.H.
Director
Division of Laboratory Systems Carlyn L. Collins, M.D., M.P.H.
Director
Laboratory Practice Assessment Branch Thomas L. Hearn, Ph.D.
Chief
The material in this report was developed and prepared by:
Model Performance Evaluation Program (MPEP) William O. Schalla, M.S.
Chief
MPEP TLI Performance Evaluation G. David Cross, M.S.
MPEP TLI Project Coordinator

Use of trade names and commercial sources is for identification only and does not constitute endorsement by the Public Health Service or the U.S. Department of Health and Human Services.

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-4559 or (770) 488-4366.

Introductory Comments

The aggregate results from a mailed questionnaire survey conducted by the Model Performance Evaluation Program (MPEP) in October 1996 of laboratories in the United States performing T-lymphocyte immunophenotyping (TLI) are presented in the following figures and tables. Of the 329 laboratories receiving this survey, 273 (83.0%) reported results. The "N" numbers appearing in each figure or table reflect the total number of laboratories responding to the specific question. For multiple response questions, the total number of responses may exceed the actual number of laboratories responding to that specific question.

The map located on page 2 reflects the enrollment in the MPEP TLI program at the time this survey was mailed, and does not reflect the current enrollment in this program.

The primary classification of all the laboratories in the MPEP TLI program at the time the survey was mailed is shown in the top figure on page 4. The primary classification of only those laboratories responding to the survey is shown in the bottom figure on the same page. The further classification of the responding laboratories is shown in the responses for questions 5(a)-5(e).

Please note that wording for questions 6 and 7, regarding the education and certification requirements of the laboratory director and supervisor, reflect current regulatory requirements related to the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88), as published in CFR 42, Part 493.


The term "single-platform method" was defined to be those methods for obtaining absolute CD4⁺ T-cell counts using a single-instrument, for example, FACSCount or Imagn 2000, or laboratory test, for example, TRAx CD4 or Zymmune assay. The term "multi-platform method" was defined to be those methods that derive absolute CD4⁺ T-cell counts by using the percent CD4⁺ T-cells obtained from a flow cytometer in combination with the absolute lymphocyte count obtained from a hematology instrument.

Responses to question 8 reflect the amount of experience necessary to perform either single-platform or multi-platform methods.


Question 27 requested information regarding the monoclonal antibody manufacturer associated with reagents for each of the cell marker combinations routinely used for performing TLI. The first page of results for this question, page 38, shows the reagents used for single-color, two-color, and three-color tests. A summary of monoclonal antibody reagents used by participant laboratories is shown on page 39. Pages 40 through 42 show the monoclonal antibody reagent panels used by the participant laboratories.

Question 44 requested information regarding the price charged for TLI performed by single-platform or multi-platform methods.


4. In the last year, has your laboratory performed TLI for HIV-infected patients?




Primary Classification of MPEP laboratories in regard to TLI testing Total number of laboratories in TLI program




Laboratories responding to questionnaire survey




5.(a) If the laboratory type shown on your mailing label (located on page one) is BLOOD BANK, please further describe your TLI testing laboratory (Check all that apply within your Blood Bank laboratory classification.):




5.(b) If the laboratory type shown on your mailing label (located on page one) is HOSPITAL, please further describe your TLI testing laboratory (Check all that apply within your Hospital laboratory classification.):




5.(c) If the laboratory type shown on your mailing label (located on page one) is HEALTH DEPARTMENT, please further describe your TLI testing laboratory (Check all that apply within your Health Department laboratory classification.):




5.(d) If the laboratory type shown on your mailing label (located on page one) is INDEPENDENT, please further describe your TLI testing laboratory (Check all that apply within your Independent laboratory classification.):




5.(e) If the laboratory type shown on your mailing label (located on page one) is OTHER, please further describe your TLI testing laboratory (Check all that apply within your Other laboratory classification.):




6.(a) Please choose from the list below the highest degree that has been awarded to your Laboratory Director and Laboratory Supervisor (Choose only one degree for each person.):




6.(b) If your Laboratory Director or Laboratory Supervisor has a degree other than M.D. or D.O., please indicate the academic discipline in which the degree was awarded (Check all that apply.):




6.(c) What organization(s) have awarded board certification to your Laboratory Director? (Check all that apply.)




6.(d) Please indicate the years of experience your Laboratory Director has in directing or supervising laboratory testing (Round off to the nearest whole number.):




6.(e) Is your Laboratory Supervisor available to provide supervision on-site?




6.(e) If no, is there another person on-site that has been assigned to provide supervision?




7.(a) Does your laboratory require that personnel who perform TLI (operate a flow cytometer and analyze resultant data) have a minimum degree?




7.(b) What are the qualifications required of your TLI testing personnel? (Check all that apply.)




7.(c) Does your laboratory require that your TLI testing personnel have professional certification?




7.(d) Please check the professional organizations that have awarded the required certification to your TLI testing personnel (Check all that apply.):




8. On average, how many months of experience do your personnel need to become proficient in performing TLI and analyzing the resultant data? (Indicate number of months of experience needed for performing multi-platform techniques. Round off to the nearest whole number.)




8. On average, how many months of experience do your personnel need to become proficient in performing TLI and analyzing the resultant data? (Indicate number of months of experience needed for performing single-platform techniques. Round off to the nearest whole number.)




9.(a) Does your laboratory require that personnel who perform TLI have training? (Choose only one.)




9.(b) What training must your laboratory personnel complete before they are considered qualified to perform TLI? (Check all that apply.)




10.(a) On average, how many TLI samples are tested in your laboratory in a month? (Number of single patient and/or blood donor samples, not tests. Round off to the nearest whole number.)




10.(b) How many TLI samples were tested in your laboratory in the last year? (Number of single patient and/or blood donor samples, not tests. Round off to the nearest whole number.)




10.(c) Has the number of requests per month for TLI to be performed by your laboratory increased, decreased, or stayed the same compared to twelve months ago? (Choose only one.)



11. In the last year, what percentage of your TLI samples have come from patients known by your laboratory to be HIV-infected? (Round off to the nearest whole number.)




12.(a) Where are your specimens collected for TLI? (Choose only one.)




12.(b) If written instructions are provided to collection site personnel for collecting, labeling, and transporting TLI specimens, who provides these instructions (Check all that apply.)

Type of Instruction	Instructions NOT provided	Testing Laboratory	Associated Institution	Person Ordering Test	Other	N=
Collecting	7	242	43	16	8	265
Labeling	11	229	46	13	7	261
Transporting	8	238	41	15	6	261


12.(c) Does your laboratory test TLI specimens collected off-site?




12.(d) When your laboratory tests TLI specimens that are collected off-site, where are the specimens collected? (Check all that apply.)




12.(e) How are the off-site TLI specimens delivered to your laboratory? (Check all that apply.)




12.(f) At what temperature are TLI specimens transported to your laboratory? (Check all that apply.)



13. On average, how many hours does it take from the time a TLI specimen is collected until the time it is delivered to your laboratory? (Round off to the nearest whole number.)




14.(a) Are the procedures your laboratory uses for labeling a suspected HIV-1-positive specimen different from the procedures you use for other specimens?




N = 272


14.(b) Universal precautions assume that all blood and body fluids are potentially infectious for blood borne pathogens. How often do your laboratory employees follow universal precautions when handling specimens for TLI? (Choose only one.)



15. Where is the hematology testing (e.g., complete blood count [CBC]) for your laboratory's TLI specimens usually performed? (Choose only one.)




16.(a) Does your laboratory use TLI specimen collection criteria to determine whether or not a specimen is acceptable for TLI?



N = 271


16.(b) What specimen collection criteria are used at your laboratory to determine whether or not a specimen is acceptable for TLI? (Check all that apply.)




17. At what temperatures does your laboratory store TLI specimens until they are processed? (Check all that apply.)

Type of Specimen	Room Temp	2 10 degrees C	Other Temp	N=
Whole Blood	268	3	0	269
Separated Cells	47	72	4	120
Other	34	17	2	51


18. When did your laboratory begin performing TLI? (Please indicate month and year only for those methods currently in use in your laboratory.)



Flow Cytometry/Hematology




19. Does your laboratory perform TLI using a flow cytometry instrument?




N=272

20.(a) How many different flow cytometer operators actually performed TLI in your laboratory over the last year?




Number of Different Operators Performing TLI

20.(b) Do any of your laboratory's flow cytometer operators routinely perform TLI on more than one flow cytometer?




N=272

20.(c) Have your flow cytometer operators received training on each of the instruments that they are required to operate?




N = 264


21. What are the quantities and manufacturers of your laboratory's flow cytometers that are used for TLI?




21. What are the quantities and manufacturers of your laboratory's hematology analyzers that are used for TLI?




22. Can multicolor analysis techniques (two or more markers tagged with different color fluorochromes as a single test) be used to perform TLI on any of the flow cytometry instruments you indicated?



23. On average, how many hours is a specimen stored at your laboratory before it is stained for TLI? (Round off to the nearest whole number.)




24.(a) Is testing for viability of TLI specimens performed by your laboratory?




N = 269


24.(b) How is testing for viability performed? (Check all that apply.)




24.(c) What is the minimum percent viability acceptable by your laboratory for TLI? (Round off the nearest whole number.)




25.(a) Does your laboratory use a whole blood lysis method for staining TLI specimens?




25.(b) Which lysis method does your laboratory use? (Check all that apply.)




25.(c) What sample staining procedure(s) does your laboratory use for TLI? (Check all that apply.)




25.(d) Does your laboratory routinely use isotype controls as part of the staining procedure?




25.(e) At what temperature does your laboratory routinely perform the staining procedure? (Choose only one.)



25.(f) Does your laboratory fix cells before TLI flow cytometry is performed?




25.(g) At what temperature does your laboratory routinely store cells after staining? (Choose only one.)



25.(h) On average, how many hours is a specimen stored at your laboratory after staining before being analyzed? (Round off to the nearest whole number.)



26. From what source did your laboratory obtain its TLI staining procedure? (Check all that apply.)




27. Please complete the table below and the table on the following page, by choosing from the lists below, the monoclonal antibody manufacturer associated with reagents for each of the cell marker combinations you routinely use for performing TLI.

					Single	-color Te	ests												
			Monoc	lonal A	ntibody	Manufa	cturers	Used											
Cell Marker	\mathbf{A}	В	\mathbf{C}	D	\mathbf{E}	\mathbf{F}	\mathbf{G}	H	K										
CD3		16	13	2					1										
CD4	1	14	11	1					1										
CD8	1	13	8	1					2										
CD19		15	16	5					1										
CD16	1	12	4	1	1			1											
CD56	1	12	17	1		1													
CD56&16	1	8	4	1															
		Two-color Tests																	
		Combinations of Monoclonal Antibody Manufacturers Used																	
Cell Marker	A/A	\mathbf{B}/\mathbf{B}	C/C	D/D	\mathbf{E}/\mathbf{E}	H/H	I/I	K/K	A/C	B/C	B/H	C/A	C/B	C/E	D/C	H/B	H/C	I/B	K/B
CD45/CD14	2	108	93	5	1	10		3										1	
CD3/CD4	1	102	84	6		9	1	2		1						1			2
CD3/CD8	1	101	86	5		9	1	2		1					1	1			2
CD3/CD16	2	25	6	2		1		1			1	1		1					
CD3/CD56	2	19	27	1				1	1			1	1		1		1	1	2
CD3/CD56&CD16		113	3	2								1	1			1			
										color Te		_							
								of Mono											
Cell Marker		A/B/B			B/B/K	B/C/C		B/D/B			C/A/C	C/C/K	H/H/H		K/B/B		K/H/H		
CD45/CD3/CD4	3		1	32		1	1		1	5				1		2			
CD45/CD3/CD8	3		1	32		1	1			4				1		2			
CD45/CD3/CD19	4		1	24				1								1			
CD45/CD3/CD56&16	6	1		24											2				
CD3/CD4/CD8	2		1	11	1	1	1			17	1	1	8	2	2		1		


Manufacturer Key:

Summary of monoclonal antibody reagents used by participant laboratories




1: one-color, 2: two-color, 3: three-color


One-color monoclonal antibody reagent panels used by participant laboratories




Two-color monoclonal antibody reagent panels used by participant laboratories




Three-color monoclonal antibody reagent panels used by participant laboratories




28.(a) How is the gating set when performing TLI on your flow cytometers? (Choose only one.)




28.(b) Which cell populations are included in the gates for analysis of lymphocyte phenotypes? (Choose only one.)



29. How are the integration windows set? (Choose only one.)




30.(a) Do you mathematically adjust your phenotype values for isotype control values?




N=270


30.(b) How do you adjust your phenotype values? (Choose only one.)




31. How often are normal cell controls used? (Choose only one.)




32. How often do your flow cytometer(s) receive preventive maintenance (e.g., cleaning of optical filters and lenses, and fluidics check)? (Choose only one.)




33.(a) How often does your laboratory optically align your flow cytometer(s)? (Choose only one.)




33.(b) What types of particles are used by your laboratory to align your flow cytometers? (Check all that apply.)




34.(a) Does your laboratory set fluorescence overlap compensation?




34.(b) What reference materials are used to set fluorescence overlap compensation? (Check all that apply.)



35.(a) What reference materials does your laboratory use to achieve the target conditions for forward angle light scatter (FALS) and fluorescence intensity (FI)? (Check all that apply.)




35.(b) Does your laboratory routinely record the instrument settings used to reach the target conditions for FALS?




N = 267


35.(c) Are these data analyzed to monitor trends or changes in instrument performance?




36.(a) How often does your laboratory standardize your flow cytometer(s)? (Choose only one.)



36.(b) What material(s) does your laboratory use to standardize your flow cytometer(s)? (Check all that apply.)




36.(c) Does your laboratory use reference standards to plot standard curves of mean channel fluorescence vs. molecules of equivalent soluble fluorochrome?




N = 247


36.(d) Does your laboratory maintain written records of the slope, intercept and correlation coefficients of the standard curves?




37. Does your laboratory perform TLI using a single-platform method?



38. What single-platform method(s) does your laboratory use? (Check all that apply.)




Before TLI results are reported, are they routinely reviewed by someone other than the person(s) who performed the tests? 39.




N=270


40. What information is included in the report returned to the person or institution initiating the request for TLI? (Check all that apply.)




41. On average, how many days elapse between receipt of the specimen in your laboratory and the time the results of the test are returned to the person or institution initiating the request for TLI? (Round off to the nearest whole number.)




42. Does your laboratory have procedures for protecting the confidentiality of TLI results?




43. On average, how many times in a month does your laboratory receive inquiries from clinicians requesting interpretation of TLI results? (Round off to the nearest whole number.)




44.(a) What is the average full price currently charged by your laboratory for TLI for each patient/blood donor sample? (Please indicate the price charged for multi-platform method. Round off to the nearest whole dollar.)




44.(a) What is the average full price currently charged by your laboratory for TLI for each patient/blood donor sample? (Please indicate the price charged for single-platform method. Round off to the nearest whole dollar.)




44.(b) Has the average full price that your laboratory charges for TLI for each patient/blood donor sample increased, decreased, or stayed the same compared to twelve months ago? (Choose only one.)




44.(c) Do you anticipate the price charged for TLI by your laboratory will increase, decrease, or stay the same in the next twelve months? (Choose only one.)




45.(a) Does your laboratory participate in an external TLI proficiency testing program?



45.(b) In which program(s) does your laboratory participate? Please exclude the CDC Model Performance Evaluation Program, since it is not designed for proficiency testing. (Check all that apply).




46.(a) In the last year, has your laboratory performed surrogate-marker tests for TLI in HIV-infected patients?




46.(b) Which surrogate-marker tests did your laboratory perform? (Check all that apply).

0



Percentage of Laboratories Responding

47.(a) In the last year, has your laboratory performed other tests for HIV-1 infection?



47.(b) Which HIV-1 tests did your laboratory perform? (Check all that apply.)

